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Glioblastoma and treatment
General Introduction
Glioblastoma multiforme (GBM) is one of the most lethal and prevalent brain tumors 
among adults with a poor prognosis [1,2]. Since 2005, standard treatment of GBM 
is according to the Stupp protocol, surgery followed by temozolomide (TMZ) and 
radiotherapy [3]. Since 2016, GBM is classified by the World Health Organization (WHO) 
into Isocitrate dehydrogenase gene (IDH)1 wildtype (wt) primary grade ІV glioma, 
representing 90% of GBMs, and IDH1-mutant (mut) being mostly secondary GBM, 
representing 10% of diagnosed GBMs. Primary GBM arises de novo that is different 
from secondary GBM developing from lower grade gliomas (LGG). The mutated IDH1 
gene encodes an enzyme with disrupted catalytic activity resulting in production of the 
oncometabolite 2-hydroxyglutarate (2-HG). An important consequence of 2-HG is that 
it alters both histone and DNA methylation patterns resulting in epigenetic changes and 
creating a CpG island methylator phenotype (G-CIMP) in GBM [4]. The methylation 
status of the O6-methylguanine-DNA methyltransferase (MGMT) gene is associated 
with better prognosis and response to Temozolomide (TMZ). IDH-mut GBM has a 
more favorable prognosis than IDH-wt GBM, a medium overall survival of 31 months 
compared to 15 months after diagnosis, respectively [5]. 
 Despite extensive current treatment of GBM the prognosis remains poor, 
including after the use of anti-angiogenic therapy with Bevacizumab (Avastin) as 
second line in relapsed tumors [6]. Several features of the tumor contribute to the 
lack of success of current therapy. GBM is characterized by highly infiltrative growth 
in the brain, which makes complete resection of the tumor impossible, decreasing the 
chance of a favorable outcome [7]. Furthermore, high chemo-radiotherapy resistance 
of GBM cells increases the occurrence of tumor relapse and a deadly outcome. 
Several mechanisms of resistance have been identified, for instance amplification of 
the EGF receptor (EGFR) gene present in around 50% of GBMs, results in EGFR 
overexpression and activation of the PI3K/AKT/mTOR survival pathway inhibiting the 
apoptotic response induced by chemotherapy. In addition, frequently mutated PTEN as 
well as TP53 mutations occurring in the majority of GBMs also facilitate tumor cell growth 
and apoptosis resistance [8]. Efforts to develop molecular strategies to overcome for 
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example TMZ resistance include pre-clinical studies using RNAi to reduce expression 
of MGMT, p53 and EGFR proteins [9]. Furthermore, combination treatments with for 
example Bevacizumab and Metformin to enhance sensitivity to chemotherapy so far 
has not prolonged overall survival [10]. Similarly, immunotherapy with PD-1, PD-L1, 
and CTLA-4 checkpoint inhibitors that have demonstrated impressive efficacy in a 
number of tumor types have thus far not shown clinical benefit in GBM [11]. Extensive 
genomic characterization of GBM has identified several genes and core pathways 
that may be relevant for disease progression but has thus far offered no handles for 
improved therapy [12].
Cancer cells resembling stem cells have been identified in various tumor types, 
including in GBM. These GBM stem cells (GSCs) are assumed to be the most 
malignant and resistant subpopulation of cells with high tumor-initiating potential and 
the ability to self-renew, thus driving tumor formation, progression and resistance to 
therapy [13-15]. Specific markers for GSCs have been reported such as cell surface 
receptor CD133 (Prominin) and transcription factors like SOX2, Nanog and Oct4, 
although providing no selective features for GSCs. Functional GSC properties such 
as their potent tumor forming ability in immune-incompetent mice and self-renewal 
potential in in vitro assays are considered better defining properties [16]. 
 GSCs are considered to be main drivers for tumor recurrence and treatment 
failure and are therefore a major focus point for research, also in our group. Identification 
of novel molecular targets in GSCs will be critical for developing better therapies 
for this deadly disease. Patient-derived GBM spheroid models, exhibit genetic and 
malignant features closely resembling the original tumor and maintain cells in a more 
stem-like state [17,18]. To study critical pathways in GBM our lab has generated such 
GBM spheroid models (also named GBM neurospheres) from leftover GBM patient 
resected tumor material [19]. These GBM spheroids are able to differentiate and form 
glial, astrocyte and neuron-like offspring upon exposure to for example Fetal Calf 
Serum (FCS) containing medium [20].
 The strong cellular heterogeneity in GBM poses another hurdle for effective 
Hurdles for effective therapy: Glioma Stem Cells and cellular heterogeneity
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The endoplasmic reticulum (ER) is an extensive membrane network that functions as 
a central intracellular organelle for protein and lipid synthesis, calcium storage and 
intracellular transport of proteins as well as the secretory pathway. Perturbation of 
ER homeostasis, such as disturbance of ATP, calcium levels or change in the redox 
status, can affect protein folding that leads to misfolded protein accumulation and 
consequently ER stress [24]. This results in the activation of an adaptive mechanism 
that promotes cell survival known as the UPR [25,26]. The UPR pathway is initiated 
via the ER transmembrane proteins IRE1, PERK and ATF6, which are kept inactive by 
binding to the ER chaperone BiP/GRP78. Upon stress BiP/GRP78 is released from 
these ER stress sensors resulting in activation of various downstream mechanisms 
ER stress/ UPR in cancer
tumor eradication. Both inter- and intra-tumoral heterogeneity has been linked with 
failure of current treatment regimens to effectively target all GBM cell populations 
in the tumor [21]. Transcriptional profiling of GBM patient samples has resulted in 
classification into proneural (PN), classic (CL) and mesenchymal (MES) subtypes 
that have been linked with several principal mutations and/ or irregularities in the 
expression of PDGFRA, IDH1, EGFR and NF1 [22]. Recently an integrated study 
including single cell sequencing, TCGA data analyses and in vitro experiments further 
demonstrated a model for classification in four cellular states, neural-progenitor-like, 
and oligodendrocyte-progenitor-like, astrocyte-like and mesenchymal-like associated 
with genetic alterations in CDK4, EGFR, PDGFRA and NF1, respectively [23]. This 
cellular heterogeneity can be attributed not only to genetic diversity, but also to signals 
derived from the tumor microenvironment (TME) and epigenetic changes that facilitate 
the high plasticity of GBM cells [23]. 
 The high level of heterogeneity and plasticity of GBM cells poses obviously a 
major hurdle for successful GBM eradication. Novel targets need to be identified that 
will tackle multiple important mechanisms involved in GBM malignancy, resistance and 
plasticity. In this thesis we hypothesized that the ER stress/ unfolded protein response 
(UPR) will provide an interesting target for therapy in GBM.
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including the arrest of general protein synthesis, enhancement of protein folding 
capacity and increased RNA and protein degradation, all aiming to restore protein-
homeostasis [27,28]. When ER stress is overwhelming the UPR will activate cell death 
programs and in cancer ER stress aggravation may provide a therapeutic strategy. In 
addition, autophagy is also part of the adaptive response activated by the UPR and 
can contribute to cell survival as well as apoptosis induction [29,30]. Autophagy is a 
ubiquitous catabolic process that involves the degradation of cytoplasmic components, 
including misfolded proteins, via the lysosomal pathway [31]. All three UPR branches 
have been reported to be able to activate autophagy [24,29,30]. 
 In cancer, oncogene-driven cell proliferation has been associated with a high 
demand for protein production and together with conditions commonly present in 
tumors, like glucose/ nutrient shortage and hypoxia, result in a state of chronic ER 
stress and a high dependency on the UPR for cell survival [25,26]. In fact, chronic UPR 
activation has been linked to many of the hallmarks of cancer, including oncogenesis, 
proliferation, metastasis and invasion, angiogenesis, therapy resistance, signals from 
the TME and inflammation [32]. Furthermore, the UPR is involved in reprogramming 
gene expression during tumor development regulating stem cell properties in both 
normal and malignant stem cells [33,34]. For example, in breast cancer cells PERK 
was shown to be required for epithelial-mesenchymal transition (EMT), metastasis 
and mammospheres formation, and affected pluripotency signals [35,36]. In colon 
cancer stem cells UPR activation triggered differentiation, thereby influencing drug 
sensitivity and proliferation state [37,38]. Together this emphasizes the potential value 
of modulating the UPR as a therapeutic approach in cancer. 
 In GBM chronic activation of the UPR has been reported evidenced among 
others by elevated BiP/GRP78 expression [39,40]. Moreover, the UPR has been 
implicated in GBM growth and progression although its role in the regulation of GSCs 
and their highly malignant properties have remained mostly elusive [41]. Therefore, 
exploration of ER stress/ UPR signaling in GSCs is of great interest in order to explore 
its importance in regulating stemness and as a possible target for therapy in GBM.
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The main aim of the research described in this thesis was to investigate ER stress/ 
UPR signaling in GSCs and explore its potential as a target for therapy in GBM. The 
importance of the UPR in contributing to acute ER stress-induced cytotoxicity was 
examined, including effects on the self-renewal potential of GSCs and the underlying 
molecular mechanisms were elucidated. For this, previously in our lab generated 
and characterized patient-derived GSC-enriched GBM neurosphere models were 
employed. 
 In chapter 2 a general introduction on the UPR and its role in cancer is 
provided. The current knowledge on the role of ER stress/ UPR in the development 
and progression of GBM and as a potential therapeutic target is evaluated. 
 In chapter 3 we investigated the therapeutic potential of ER stress induction in 
different GBM neurosphere models. We started by analyzing the UPR activation status 
in GBM patients using a tissue microarray (TMA) and immunohistochemistry. Next, we 
examined sensitivity to the ER stress-inducing agents, thapsigargin and tunicamycin, 
using short-time cytotoxicity assays and the effect on self-renewal potential by long-
term spheroid formation assays. The contribution of the three UPR branches in ER 
stress sensitivity and impact on self-renewal was determined using pharmacological 
inhibitors, short hairpin RNAs and CRISPR/Cas9 knockout approaches. In Chapter 
3.1 (appendix), we explored correlations between expression of the hypoxic marker 
GLUT1 and the UPR proteins BiP/GRP78, ATF4 and XBP1 using the same clinical 
GBM specimens (TMA) as in chapter 3. In addition, the use of digital image analyses 
for determining protein levels was discussed in more detail.
 In chapter 4 we examined the effect of PERK inhibition on self-renewal potential 
of GSCs in the absence of acute stress and applied comparative transcriptomics to 
examine possible underlying mechanisms of regulation. For this, differential expression 
analysis on generated mRNA NGS datasets was performed obtained from controls, 
PERK inhibitor-treated and serum differentiated GBM neurospheres. 
 The involvement of autophagy in UPR-induced signaling in GBM neurospheres 
was addressed in chapter 5. In this preliminary study the activation of different 
autophagy molecular markers were evaluated upon extrinsic ER stress induction 
by thapsigargin in GBM neurospheres and differentiated counterparts and related to 
Scope of the thesis
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thapsigargin sensitivity. The autophagic flux was studied and the transcription levels of 
genes involved in autophagy also were compared.
 Finally, in chapter 6 the findings of this thesis are summarized. A general 
discussion with conclusion of the chapters and future perspectives are presented. 
thapsigargin sensitivity. The autophagic flux was studied and the transcription levels of 
genes involved in autophagy also were compared.
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